Cochrane · systematic review · CD006077
Allopurinol for chronic gout
Seth, R, Kydd, ASR, Buchbinder, R, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
11
No studies
9
Included studies
NR
No studies 9 · 42.9%Ungraded 1 · 4.8%Very low 0 · 0%Low 4 · 19%Moderate 7 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Allopurinol compared with placebo for chronic gout
Population: people with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acute gout attacks Allopurinol vs placebo | RR 0.64 [0.12, 3.52] | 1 study · 51 participants | Moderate Downgraded: imprecision |
Proportion achieving target serum urate Allopurinol vs placebo | RR 49.11 [3.15, 765.58] | 1 study · 51 participants | Moderate Downgraded: imprecision |
Pain reduction Allopurinol vs placebo | no estimate extracted | 1 study · 51 participants | Ungraded |
Function Allopurinol vs placebo | no estimate extracted | NR | No studies |
Tophus regression Allopurinol vs placebo | no estimate extracted | NR | No studies |
Withdrawal due to adverse events Allopurinol vs placebo | RR 1.36 [0.61, 3.08] | 2 studies · 453 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events Allopurinol vs placebo | RR 1.93 [0.48, 7.8] | 2 studies · 453 participants | Moderate Downgraded: risk of bias, imprecision |
Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout
Population: people with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acute gout attacks Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | RR 0.89 [0.71, 1.1] | 3 studies · 1136 participants | Low Downgraded: risk of bias, imprecision |
Proportion achieving target serum urate Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | RR 0.56 [0.48, 0.65] | 4 studies · 2618 participants | Low Downgraded: risk of bias, imprecision |
Pain reduction ‐ not measured Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | no estimate extracted | NR | No studies |
Function ‐ not measured Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | no estimate extracted | NR | No studies |
Tophus regression Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | no estimate extracted | NR | No studies |
Withdrawal due to adverse effects Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | RR 0.89 [0.62, 1.26] | 3 studies · 2555 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse effects Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily | RR 1.13 [0.71, 1.82] | 3 studies · 2556 participants | Moderate Downgraded: risk of bias, imprecision |
Allopurinol compared with benzbromarone for people with chronic gout
Population: people with chronic gout
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acute gout attacks Allopurinol vs benzbromarone | RR 0.28 [0.01, 6.58] | 1 study · 55 participants | Low Downgraded: risk of bias, imprecision |
Proportion achieving target serum urate Allopurinol vs benzbromarone | RR 0.79 [0.56, 1.11] | 2 studies · 101 participants | Moderate Downgraded: risk of bias |
Pain reduction ‐ not measured Allopurinol vs benzbromarone | no estimate extracted | NR | No studies |
Function ‐ not measured Allopurinol vs benzbromarone | no estimate extracted | NR | No studies |
Tophus regression ‐ not reported Allopurinol vs benzbromarone | no estimate extracted | NR | No studies |
Withdrawal due to adverse events Allopurinol vs benzbromarone | RR 0.8 [0.18, 3.58] | 2 studies · 91 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse effects Allopurinol vs benzbromarone | no estimate extracted | NR | No studies |